Case report of curative resection after preoperative bevacizumab and sintilimab therapy in hepatocellular carcinoma with lymph node metastasis.

Shujie Pang, Yingcheng Yang, Zhe Sun, Ning Yang

Abstract read

In one paragraph

Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Shujie Pang *Department V of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, #700 Moyu Road, Shanghai, 201805, People's Republic of China.

Yingcheng Yang *Department V of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, #700 Moyu Road, Shanghai, 201805, People's Republic of China. yangyingcheng1221@aliyun.com.

Zhe Sun *Department V of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, #700 Moyu Road, Shanghai, 201805, People's Republic of China.

Ning YangDepartment V of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, #700 Moyu Road, Shanghai, 201805, People's Republic of China. lancet00@163.com.

Funding

special clinic project of Shanghai 20234Y0264

6 · The paper itself

Abstract

Hepatocellular carcinoma with lymph node metastasis (HCC-LNM) is relatively rare, and optimal management remains controversial. We report two cases of HCC with lymph node metastasis treated with three cycles of Sintilimab and Bevacizumab therapy. The metastatic lymph nodes demonstrated partial shrinkage, with extensive coagulative necrosis and complete absence of viable tumor cells. Primary liver lesions demonstrated a partial response to systemic therapy. Both patients subsequently achieved curative resection. No recurrence occurred during postoperative follow-up (20 months for Case 1; 16 months for Case 2). Collectively, preoperative immunotherapy and targeted therapy has the potential to enable curative outcomes in patients with solitary HCC lymph node metastasis, although validation in larger studies is required.

Indexed as

Hepatocellular carcinomaImmunotherapyLymph node metastasisSurgery

Identifiers

PMID41217735

DOI10.1007/s12672-025-03836-x

PMCPMC12605659

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.